192 related articles for article (PubMed ID: 29843087)
21. Anticoagulation resumption after intracranial hemorrhage in patients treated with VKA and DOACs.
Poli D; Antonucci E; Vignini E; Martinese L; Testa S; Simioni P; Pengo V; Pignatelli P; Falanga A; Masciocco L; Barcellona D; Ciampa A; Chiarugi P; Paparo C; Ageno W; Palareti G;
Eur J Intern Med; 2020 Oct; 80():73-77. PubMed ID: 32522446
[TBL] [Abstract][Full Text] [Related]
22. Coagulation activation after discontinuation of VTE treatment with different oral anticoagulants and impact on 12-month clinical outcomes.
Beyer-Westendorf J; Gehrisch S; Stange T; Tittl L; Siegert G; Weiss N
Thromb Res; 2015 Aug; 136(2):261-6. PubMed ID: 26071672
[TBL] [Abstract][Full Text] [Related]
23. Direct oral anticoagulants are effective and safe for the treatment of venous thromboembolism associated with gynecological cancers.
Shimizu A; Sawada K; Shiomi M; Kawano M; Matsumoto Y; Takiuchi T; Kodama M; Kobayashi E; Hashimoto K; Mabuchi S; Ueda Y; Tomimatsu T; Kimura T
Int J Gynaecol Obstet; 2019 Nov; 147(2):252-257. PubMed ID: 31420876
[TBL] [Abstract][Full Text] [Related]
24. [Oral anticoagulants for primary and secondary prevention of venous thromboembolism].
Gavorník P; Dukát A; Gašpar Ľ; Gubo G; Hučková N
Vnitr Lek; 2016; 62(9):746-750. PubMed ID: 27715076
[TBL] [Abstract][Full Text] [Related]
25. Bleeding Outcomes of Direct Oral Anticoagulants and Vitamin K Antagonists for Acute Venous Thromboembolism: A Cross-Sectional Study.
Javaid Z; Awan SA; Babar M; Khawaja I; Qamar Z
Cureus; 2024 May; 16(5):e60616. PubMed ID: 38894767
[TBL] [Abstract][Full Text] [Related]
26. Is it reasonable to use a lower DOAC dose in some patients with VTE? NO.
Dentali F; Fantoni C
Intern Emerg Med; 2017 Aug; 12(5):565-567. PubMed ID: 28656545
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of anticoagulation selection for acute venous thromboembolism.
Badreldin H; Nichols H; Rimsans J; Carter D
J Thromb Thrombolysis; 2017 Jan; 43(1):74-78. PubMed ID: 27592341
[TBL] [Abstract][Full Text] [Related]
28. Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms.
Huenerbein K; Sadjadian P; Becker T; Kolatzki V; Deventer E; Engelhardt C; Griesshammer M; Wille K
Ann Hematol; 2021 Aug; 100(8):2015-2022. PubMed ID: 33216197
[TBL] [Abstract][Full Text] [Related]
29. Case Fatality Rates of Recurrent Thromboembolism and Bleeding in Patients Receiving Direct Oral Anticoagulants for the Initial and Extended Treatment of Venous Thromboembolism: A Systematic Review.
Gómez-Outes A; Lecumberri R; Suárez-Gea ML; Terleira-Fernández AI; Monreal M; Vargas-Castrillón E
J Cardiovasc Pharmacol Ther; 2015 Sep; 20(5):490-500. PubMed ID: 25802423
[TBL] [Abstract][Full Text] [Related]
30. Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients Aged 80 Years and Older.
Manckoundia P; Nuemi G; Hacquin A; Menu D; Rosay C; Vovelle J; Nuss V; Baudin-Senegas C; Barben J; Putot A
Int J Environ Res Public Health; 2021 Apr; 18(9):. PubMed ID: 33922331
[TBL] [Abstract][Full Text] [Related]
31. Comparative safety and effectiveness of rivaroxaban versus VKAs in patients with venous thromboembolism. A Danish nationwide registry-based study.
Sindet-Pedersen C; Langtved Pallisgaard J; Staerk L; Gerds TA; Fosbøl EL; Torp-Pedersen C; Gislason G; Olesen JB
Thromb Haemost; 2017 Jun; 117(6):1182-1191. PubMed ID: 28300865
[TBL] [Abstract][Full Text] [Related]
32. Assessment of quality of life, satisfaction with anticoagulation therapy, and adherence to treatment in patients receiving long-course vitamin K antagonists or direct oral anticoagulants for venous thromboembolism.
Keita I; Aubin-Auger I; Lalanne C; Aubert JP; Chassany O; Duracinsky M; Mahé I
Patient Prefer Adherence; 2017; 11():1625-1634. PubMed ID: 29026288
[TBL] [Abstract][Full Text] [Related]
33. Anticoagulant therapies for acute venous thromboembolism among a cohort of patients discharged from Canadian urban and rural hospitals.
Bungard TJ; Ritchie B; Bolt J; Semchuk WM
BMJ Open; 2018 Oct; 8(10):e022065. PubMed ID: 30385440
[TBL] [Abstract][Full Text] [Related]
34. A Comprehensive Overview of Direct Oral Anticoagulants for the Management of Venous Thromboembolism.
Comerota AJ; Ramacciotti E
Am J Med Sci; 2016 Jul; 352(1):92-106. PubMed ID: 27432042
[TBL] [Abstract][Full Text] [Related]
35. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
Beyer-Westendorf J; Ageno W
Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
[TBL] [Abstract][Full Text] [Related]
36. Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review.
Gómez-Outes A; Suárez-Gea ML; Lecumberri R; Terleira-Fernández AI; Vargas-Castrillón E
Vasc Health Risk Manag; 2014; 10():627-39. PubMed ID: 25404858
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of direct oral anticoagulants for the treatment of venous thromboembolism in the oncology population.
Hedvat J; Howlett C; McCloskey J; Patel R
J Thromb Thrombolysis; 2018 Nov; 46(4):483-487. PubMed ID: 30191357
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of anticoagulant agents in patients with venous thromboembolism and cancer: A network meta-analysis.
Vedovati MC; Giustozzi M; Bonitta G; Agnelli G; Becattini C
Thromb Res; 2018 Oct; 170():175-180. PubMed ID: 30196195
[TBL] [Abstract][Full Text] [Related]
39. DOAC-Remove abolishes the effect of direct oral anticoagulants on activated protein C resistance testing in real-life venous thromboembolism patients.
Kopytek M; Ząbczyk M; Malinowski KP; Undas A; Natorska J
Clin Chem Lab Med; 2020 Feb; 58(3):430-437. PubMed ID: 31539350
[TBL] [Abstract][Full Text] [Related]
40. Self-reported adherence to anticoagulation and its determinants using the Morisky medication adherence scale.
Castellucci LA; Shaw J; van der Salm K; Erkens P; Le Gal G; Petrcich W; Carrier M
Thromb Res; 2015 Oct; 136(4):727-31. PubMed ID: 26272305
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
